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Abstract
Background: Maintenance of healthy bone requires the balanced activities of osteoclasts (OCs), which resorb bone, and
osteoblasts, which build bone. Disproportionate action of OCs is responsible for the bone loss associated with postmenopausal
osteoporosis and rheumatoid arthritis. NF-kB inducing kinase (NIK) controls activation of the alternative NF-kB pathway, a critical
pathway for OC differentiation. Under basal conditions, TRAF3-mediated NIK degradation prevents downstream signaling, and
disruption of the NIK:TRAF3 interaction stabilizes NIK leading to constitutive activation of the alternative NF-kB pathway.
Methodology/Principal Findings: Using transgenic mice with OC-lineage expression of NIK lacking its TRAF3 binding
domain (NT3), we now find that alternative NF-kB activation enhances not only OC differentiation but also OC function.
Activating NT3 with either lysozyme M Cre or cathepsinK Cre causes high turnover osteoporosis with increased activity of
OCs and osteoblasts. In vitro, NT3-expressing precursors form OCs more quickly and at lower doses of RANKL. When
cultured on bone, they exhibit larger actin rings and increased resorptive activity. OC-specific NT3 transgenic mice also have
an exaggerated osteolytic response to the serum transfer model of arthritis.
Conclusions: Constitutive activation of NIK drives enhanced osteoclastogenesis and bone resorption, both in basal
conditions and in response to inflammatory stimuli.
Citation: Yang C, McCoy K, Davis JL, Schmidt-Supprian M, Sasaki Y, et al. (2010) NIK Stabilization in Osteoclasts Results in Osteoporosis and Enhanced
Inflammatory Osteolysis. PLoS ONE 5(11): e15383. doi:10.1371/journal.pone.0015383
Editor: Maria G. Castro, University of California Los Angeles and Cedars-Sinai Medical Center, United States of America
Received July 29, 2010; Accepted August 31, 2010; Published November 8, 2010
Copyright:  2010 Yang, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National Institutes of Health (NIH), grant numbers AR052705 and EB007568 (DVN) and AR52921 and 63181 (RF), the
Barnes-Jewish Foundation (DVN), the Children’s Discovery Institute (RF and DVN), and the Arthritis Foundation (RF). Histological and microCT analysis was
supported in part by the Washington University Center for Musculoskeletal Research NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS), grant number AR057235. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: novack@wustl.edu
Introduction
Osteoclasts (OCs) are the only cells capable of bone resorption, a
process required for both normal bone homeostasis and patholog-
ical bone loss [1]. These terminally differentiated, multinucleated
cells are derived from precursors in the monocyte/macrophage
lineage. The primary cytokine mediating OC differentiation is
receptor activator of NF-kB ligand (RANKL), a member of the
TNF superfamily. RANKL, working via its receptor RANK,
commits early precursors to the OC fate, and causes fusion of these
preosteoclasts to generate mature multinucleated cells. OCs attach
to the bone surface, via avb3 integrins, forming a tight sealing zone
that delineates a resorptive lacuna into which acid and matrix-
degrading enzymes are secreted [2]. The actin ring is a distinctive
cytoskeletal structure that OCs must form in order to generate a
sealing zone. Many signaling pathways, including those down-
streamofRANKL,appeartocontributetoactinring formation,but
specific transcriptional programs have not been defined.
Even before the identification of RANKL, NF-kB was identified
as an important pathway in the context of bone when it was found
that mice lacking both the p50 and p52 subunits were
osteopetrotic, with a complete absence of OCs [3,4]. More recent
studies have defined two distinct NF-kB pathways, both of which
are activated by RANKL in osteoclast lineage cells [5]. The
primary role of the classical pathway is to allow survival of OC
precursors [6,7]. In contrast, the alternative or non-canonical NF-
kB pathway controls OC differentiation, but not survival [8,9]. It
is initiated by the upstream kinase NIK, and culminates in
transcription of target genes by RelB/p52 NF-kB dimers. This
pathway is negatively regulated at 2 levels, by the instability of
NIK protein and the retention of RelB in the cytoplasm by p100.
In unstimulated cells, NIK interacts with TRAF3, leading to
ubiquitination by cIAPs and degradation by the proteosome,
keeping total cellular NIK levels very low [10,11]. Upon RANKL
stimulation, TRAF3 is degraded and NIK is stabilized in the cell.
NIK then promotes processing of p100 to p52 by the proteosome,
leading to accumulation of active RelB/p52 dimers in the nucleus.
We have previously shown that absence of NIK or RelB in OCs
blocks osteoclastogenesis, in vitro, and pathological osteolysis in the
context of inflammation and bone metastasis, but has little effect on
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the globally NIK-deficient mouse, the complete lack of OC
differentiation, in vitro, and the effect of NIK deletion in other
cell types, in vivo, limited our ability to fully delineate the role of
NIK and the alternative NF-kB pathway in the OC lineage.
Recently, constitutive activation of NIK – by direct mutation or
mutation of its negative regulators cIAP1/2 and TRAF3 – has been
identified in multiple myeloma [13,14]. This aberrant NIK
activation leads to increased cell survival and proliferation of
malignant plasma cells. Although it did not cause myeloma in mice,
transgenicexpression of a constitutively active NIK in B cells caused
growth factor independent B cell hyperplasia [15]. This constitu-
tively active NIK allele – NIKDT3– lacks the TRAF3 binding
domain, preventing the degradation that normally keeps NIK levels
low in resting cells. Using mice expressing this mutant NIK allele in
OC lineage cells, we describe the effects of constitutive NIK
activation in OCs both in vivo and in vitro. We find that NIKDT3
transgenic mice are osteoporotic at baseline, and are much more
sensitive to inflammatory osteolysis than nontransgenic littermates
using the serum transfer model of arthritis. In vitro, NIKDT3 drives
more robust OC differentiation and generates more active OCs
characterized by an enlarged actin ring, indicating that the
alternative NF-kB pathway controls not only OC differentiation
but also resorptive activity. Thus, inhibition of NIK is a promising
therapeutic strategy for preventing pathological bone loss, while
activation of NIK, such as might occur with cIAP antagonists, may
accelerate bone loss due to OC activation.
Results
Expression of stabilized NIK in OCs leads to decreased
bone mass
We obtained transgenic mice in which mutant NIK lacking the
TRAF3 binding domain (aa78–84) was knocked into the ROSA26
locus, flanked upstream by a loxP-Neo
R.STOP-loxP cassette
(Fig 1A) [15]. This NIKDTRAF3 (hereafter referred to as NT3)
protein cannot bind to the TRAF3/TRAF2/cIAP complex and is
stabilized, even in resting cells. In order to target NT3 to the
osteoclast lineage, we mated homozygous NT3 mice to heterozy-
gous cathepsin K (catK)-Cre and lysozyme M (lysM)-Cre lines,
both of which have previously been shown to mediate deletion of
floxed alleles in OCs [16–21]. In each case, all of the progeny had
one NT3 allele and half were Cre+ driving expression of NT3 in
the OC lineage. We refer to Cre+ progeny from catK-Cre matings
as NT3.catK, and those from lysM-Cre matings as NT3.lysM.
Neither catK-Cre nor lysM-Cre heterozygous mice have detect-
able OC phenotypes. Therefore, we used Cre negative littermates
as controls (Ctl) in all experiments. PCR analysis of genomic DNA
isolated from cultures of bone marrow macrophages (BMMs)
treated with RANKL, amplifying across the loxP sites, demon-
strates that NT3.catK precursors deleted the STOP sequence
beginning on day 2 of RANKL treatment, as seen by the
appearance of the smaller amplicon (Fig 1B). NT3.lysM BMMs
have completely deleted the STOP before exposure to RANKL
(Fig 1C). Immunoblots show an increase in NIK protein that
corresponds with the Cre-mediated deletion of the STOP
sequence (Fig 1D, E). Congruently, p52 levels are increased at
day 4 in NT3.catK cultures (Fig 1F), and in unstimulated
NT3.lysM BMMs (Fig 1G). Levels of nuclear RelB are also
elevated in NT3.lysM cells (Fig 1H). Thus, NT3 expression
stabilizes NIK and drives processing of p100 to p52 and nuclear
translocation of RelB, indicating activation of alternative NF-kB.
Nuclear p65 levels and phosphorylation of IkBa are also enhanced
in NT3.lysM BMMs, compared to Ctl (Fig 1H,I), demonstrating
that classical NF-kB is also activated by the transgene.
We next analyzed the bone phenotype of NT3.catK and
NT3.lysM mice at 8 weeks of age by microCT, compared to age
and sex matched Ctl mice. Both NT3 lines had a significantly
Figure 1. Expression of NIKDT3 induced by both catK-Cre and lysM-Cre. A. Diagram of NT3 locus. NIKDT3 (NT3) cDNA was knocked into the
ROSA26 locus, flanked upstream by a loxP- Neo
R.STOP-loxP cassette. Cre-mediated loxP recombination removes the Neo
R.STOP sequence, putting
NT3 under control of the ROSA 26 promoter. Black arrows indicate the pair of primers used to amplify across the loxP. B–C. Genomic DNA
amplification across the loxP sites using NT3.catK (B) and NT3.lysM (C) BMMs cultured with 20 ng/ml RANKL for up to 4 days. ,3kb STOP and ,300bp
lox bands are generated before and after Cre-mediated deletion, respectively. The left most lanes (-) are negative controls with no genomic DNA in
PCR reactions. D–E. Western blot analysis of NT3 expression in total cell lysates, using BMMs cultured as in B. NIK KO BMMs serve as a negative
control. F–G. p100/p52 processing was assessed by Western blot in total cell lysates from Ctl and NT3.catK BMMs cultured in RANKL for the indicated
times, or in unstimulated NT3.lysM BMMs. H. Evaluation of RelB and p65 levels in nuclear extracts of NT3.lysM BMMs. I. Western blot analysis of IkBa
phosphorylation in NT3.lysM BMM total lysates.
doi:10.1371/journal.pone.0015383.g001
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NT3.catK and by 40% in NT3.lysM. Bone mineral density (BMD)
was less, accompanied by increased trabecular spacing and
decreased trabecular numbers, indicating decreased bone mass
in the trabecular compartment of NT3 mice (Fig 2). Cortical bone
area was also significantly decreased in NT3.catK mice (not
shown). In order to determine how the OC and osteoblast (OB)
compartments were affected by the transgene, we examined
NT3.catK tibias by histomorphometry. Both the number of OCs
and the trabecular bone surface covered by OCs was increased to
approximately double that of Ctl (Fig 3A). Despite an absence of
transgene expression in OBs in NT3.catK mice, the number of
OBs and the bone formation rate were also significantly elevated
compared to Ctl (Fig 3B), likely reflecting coupling of OC and OB
activities. Supporting these histomorphometric results, serum
markers of both OC and OB activity were also increased in the
8 week old NT3.catK mice (Fig 4). Thus, constitutive expression of
NIK in the OC lineage leads to high turnover osteoporosis.
Constitutive NIK activation enhances osteoclastogenesis
and bone resorption in vitro
To determine the effect of NT3 on osteoclastogenesis in vitro,
NT3.catK BMMs were cultured in various doses of RANKL, then
stained for tartrate resistant acid phosphatase (TRAP), a marker of
OC differentiation. The greatest difference between the transgene
positive and Ctl cultures was at suboptimal doses (20–40 ng/mL)
of RANKL. At these doses, NT3.catK multinucleated TRAP+
OCs formed earlier than Ctl, and at both 4 and 6 days of culture
they also formed more OCs (Fig 5A,B). Similarly, NT3.lysM
BMMs also form more OCs than controls at low RANKL doses
(2165 vs.1262at 20 ng/ml; 4065v s1 7 63 at 40 ng/ml; p,0.05
for both doses). At higher doses, similar numbers of confluent OCs
formed, although this occurred earlier in NT3-expressing cultures
(not shown). Quantitative RT-PCR analysis demonstrated that the
differentiation markers NFATc1, b3 integrin, DC-Stamp and
calcitonin receptor were all induced to higher levels in the
presence of the NT3 transgene, in cells cultured with 20 ng/ml
RANKL (Fig 5C).
When OC precursors were cultured on bone slices for 10 days
in 20 ng/ml RANKL, NT3.catK cultures showed more than 3-
fold more resorbed area than Ctl cultures (Fig 6A). In order to
determine whether NT3.catK OCs had increased activity per cell,
we used a short-term resorption assay in which equal numbers of
preosteoclasts, generated on plastic with RANKL for 2 days, were
plated on bone slices for 2 more days, and resorption was assessed
by measurement of CTX released into the media. Cells were
cultured in 100 ng/ml RANKL, a dose at which osteoclastogen-
esis was comparable in NT3.catK and Ctl cultures, as determined
by counting the number of OCs with actin rings on each bone
slice. In this assay, CTX release was again more than 3-fold higher
in NT3-expressing cells (Fig 6B). The actin ring is the critical
cytoskeletal structure required for an OC’s resorptive ability. We
therefore stained the OCs on bone with Alexa488-phalloidin, and
found that the actin rings of NT3-catK cells were significantly
larger than Ctl (Fig 6C). These results suggest that the alternative
NF-kB pathway controls not only OC differentiation, but also OC
activity.
Figure 2. Decreased bone mass in both NT3.catK and NT3.lysM in vivo. Left femurs of 8 weeks old mice from NT3.catK (A) and NT3.lysM (B)
mice and their littermate controls (Ctl) were scanned by microCT. BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Th (trabecular
thickness), Tb.Sp (trabecular spacing), and BMD (bone mineral density) were analyzed. * p,0.05;* *p,0.01; *** p,0.001 versus controls., n=16
NT3.catK; n=10 Ctl; n=6 NT3.lysM; n=10 Ctl.
doi:10.1371/journal.pone.0015383.g002
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Serum transfer arthritis (STA), is a well-characterized model of
inflammatory bone loss that mimics rheumatoid arthritis [22]. In
STA, serum from arthritic K/BxN mice is injected intraperitone-
ally into naı ¨ve mice, causing joint-centered inflammation and local
OC-mediated bone erosion. We injected 8-week old NT3.catK
and Ctl littermates with serum on days 0 and 2, then followed the
inflammatory response by measuring hindpaw thickness. Bone
resorption was assessed by measurement of serum CTX and
imaging of joints by microCT. Both groups responded with paw
swelling, although the peak at day 5–6 was slightly lower in the
NT3-expressing group (Fig 7A). Despite this small decrease in
inflammation, the level of bone resorption was twice as high in
NT3.catK mice compared to Ctl, as shown by serum CTX levels
(Fig 7B). MicroCT analysis of the paws and knee joints also
showed increased erosion of cortical bone in NT3.catK mice
(Fig 7C–E). Thus, expression of activated NIK only in the OC
lineage enhances the osteolytic response to inflammation.
Discussion
Unlike the classical NF-kB pathway, which is activated by a
wide array of inflammatory and infectious stimuli, the alternative
NF-kB pathway is activated by only a small subset of cytokines,
including RANKL, Ltb, CD40L and BAFF [5]. Knockouts of
various alternative pathway components have demonstrated roles
in maturation of B cells [23] and induction of TH17 cells [24], as
well as differentiation of osteoclasts [8], suggesting that this
pathway might be a relatively specific target for autoimmune
diseases, especially those associated with bone loss. The stability of
NIK is one of the key control points for activation of the
alternative NF-kB pathway. Recent studies of mutations in
multiple myelomas revealed that NIK, or more frequently proteins
such as TRAF3 and cIAPs that control NIK degradation, are
targets for mutation in these tumors [13,14]. This observation led
to generation of transgenic mice expressing a stabilized form of
NIK, using a tissue-specific Cre-mediated activation approach,
Figure 3. Histomorphometry analysis of NT3.catK mice. 8 week old NT3.catK mice were labeled calcein 9 and 2 days prior to sacrifice. Left
tibias were fixed and sectioned for histomorphometric analysis. A. Osteoclast-related parameters, N.Oc/BS (number of osteoclasts per bone surface)
and Oc.S/BS (osteoclast surface per bone surface), are shown. B. Osteoblast-related parameters include N.Ob/BS (number of osteoblasts per bone
surface) and BFR (expressed as bone formation rate per bone surface). * p#0.05;* *p#0.01 versus controls. n=6 Ctl; n=4 NT3.catK.
doi:10.1371/journal.pone.0015383.g003
Figure 4. Serum markers of bone resorption and formation activity in NT3.catK mice. Serum from 8-week old control and NT3.catK mice
were collected and subject to CTX (A) and osteocalcin (B) assay. * p,0.001 versus controls. n=21 Ctl; n=17 NT3.catK.
doi:10.1371/journal.pone.0015383.g004
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RANKL. Cells were fixed and TRAP-stained at day 4 (A) and day 6 (B). TRAP-positive multinucleated cells in each well were counted, n=6–9. * p,0.05;
** p,0.01 versus Ctl. Scale bar indicates 500 mm. C. Ctl and NT3.catK BMMs were cultured with 20 ng/ml RANKL, and RNA was prepared on day 0, 2,
and 4, to monitor the transcription levels of indicated OC differentiation markers by quantitative real time RT-PCR, normalized to levels of Gapdh.
doi:10.1371/journal.pone.0015383.g005
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activation [15]. By expressing this NT3 transgene in the OC
lineage, we now describe the effects of NIK activation on bone
homeostasis and inflammatory bone loss.
In order to express NT3 in OCs, we utilized two Cre transgenic
lines that have previously been shown to delete floxed alleles in this
lineage. LysM-Cre mediates deletion in neutrophils, macrophages,
and OCs [16], while CatK-Cre is more specific to the OC lineage,
deleting at the preosteoclast stage [19]. We found that both
NT3.lysM and NT3.catK mice had severe osteoporosis at 8 weeks
of age, with an approximate 50% loss in trabecular bone volume.
In vitro, osteoclastogenesis occurred at lower doses of RANKL in
both NT3.lysM and NT3.catK BMMs, even though NT3.catK
BMMs did not show expression of NT3 until they had been
cultured in RANKL for 2 days. Nevertheless, even in low doses of
RANKL, only an additional 2 days were sufficient for full OC
differentiation in NT3.catK cells. Overall, NT3.catK BMMs
differentiated more quickly and at lower doses of RANKL than Ctl
BMMs, and expressed higher levels of OC differentiation markers
NFATc1, b3 integrin, DCStamp and calcitonin receptor. The
similarity in phenotypes, in vivo and in vitro, between the earlier
expression of NT3 in the lysM line and the later activation in the
catK line suggest that the major effects of the alternative pathway
occur after commitment to the OC lineage.
In addition to finding increased OC differentiation, our in vitro
experiments indicated that NIK activation also enhances the
resorptive capacity of each OC. When we plated equal numbers of
preosteoclasts on bone at high doses of RANKL, which further
normalizes the numbers of OCs formed, we still saw a large
increase in bone resorption by NT3-expressing OCs. Intriguingly,
actin rings were 3-fold larger in area in NT3.catK OCs compared
to Ctl OCs, extending almost to the cell edge. Preliminary
experiments suggest that even on plastic, NT3 drives increased
expression of a subset of cytoskeleton-associated proteins (J.L.
Davis and D.V. Novack, unpublished data). Although there are a
number of suggestions in the literature that the cytoskeleton can
alter signaling pathways including NF-kB [25–27], there are no
direct studies indicating that the alternative pathway can regulate
Figure 6. Increased activity of NT3.catK osteoclasts in vitro. A–B. Control and NT3.catK OC precursors were cultured with 20 ng/ml RANKL on
bone slices for 10 days. (A)Bone slices were fixed and stained with peroxidase-conjugated wheat germ agglutinin to visualize the resoprtion pits. (B)
Pit area was quantitated on bone slices from A. n=3 per condition. C–E. Preosteoclasts were generated on plastic using 100 ng/ml RANKL for 2 days,
then lifted and replated on bone for culture with 100 ng/ml RANKL for an additional 2 days. (C) Media was collected for culture CTX assay. n=3. (D)
Bone slices were fixed and stained with Alexa 488 phalloidin to visualize actin rings. Scale bar, 100 mm. (E) Actin ring area was quantified. * p,0.05;
** p,0.01 versus controls.
doi:10.1371/journal.pone.0015383.g006
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the OC must secrete enzymes and acid to accomplish bone
resorption. Our observation that NT3 OCs are highly efficient
bone resorbers may indicate NIK also plays a role in these
processes.
Exposure of OC precursors to RANKL causes NIK-dependent
processing of p100 to p52, an event necessary for OC
differentiation in vitro [8]. Expression of the stabilized form of
NIK, NT3, increased this processing event and enhanced
osteoclastogenesis. However, we do not know whether this
traditional role for NIK is responsible for all of the observed
stimulatory effects on OCs. Ablation of NIK causes accumulation
of p100 which inhibits classical NF-kB signaling by binding p65,
although this does not contribute significantly to the observed
block in OC differentiation [6,8]. Nevertheless, activation of the
classical pathway by NT3 could contribute to increased OC
numbers, either by supporting the differentiation program or
inhibiting apoptosis. In other cell types, NIK has been shown to
impact STAT3 signaling [24,28] and ERK activation [15,29], and
activation of these pathways could impact the OC as well. Further
studies will be required to determine all of the pathways impacted
by NIK stabilization in the OC.
The most common form of systemic bone loss is postmeno-
pausal osteoporosis caused by estrogen deficiency. In the early
phases of this disease, the activity of both OCs and OBs is
increased leading to high bone turnover. However, bone
resorption and formation are not balanced, and the net effect is
bone loss, primarily in the trabeculae [1]. Most studies have
focused on stimulation of OCs as the primary event. In physiologic
bone remodeling, the differentiation and activity of OBs is coupled
to that of OCs via as yet incompletely defined factors, and in early
osteoporosis the OB activation is also thought to be secondary to
the OC. Analysis of NT3.catK mice demonstrated that, at
baseline, the number of OCs was increased, as were serum levels
of CTX, a marker of OC activity, indicating that bone resorption
was increased. OB number and bone formation rate were also
elevated along with osteocalcin, a serum marker of OB activity.
This phenotype of low bone mass with elevated OC and OB
activity is known as high turnover osteoporosis and mimics the
early postmenopausal state.
Another common context for pathological bone loss is
rheumatoid arthritis, in which inflammatory mediators such as
TNFa promote OC differentiation and activation leading to local
osteolysis. We have previously shown that NIK2/2 mice are
resistant to periarticular bone erosion in the STA model of
rheumatoid arthritis, in the context of normal inflammation,
suggesting that NIK is important for the osteolytic response itself
[12]. We now find that the constitutive NIK activation in
NT3.catK mice leads to an exaggerated osteolytic response to
STA. MicroCT scanning shows increased pitting of cortical bone
around the joints leading to a measurable decrease in overall BMD
at the knee. In this model, bone resorption is stimulated due to
upregulation of RANKL and TNFa in the joints. Given the
enhanced sensitivity of NT3-expressing OC precursors to
RANKL, it is not surprising that there is increased bone erosion
in vivo. Additionally, NT3.lysM precursors are capable of
Figure 7. Increased bone erosion in NT3.catK mice during serum transfer arthritis. A. Hindpaw thickness was measured bilaterally every
day following serum injection on day 0 and 2. n=8 Ctl; n=12 NT3.catK. B. Serum was collected on day 0 and 7 and used for CTX assay to measure OC
activity. n=5 per group. C–E. Mice were sacrificed on day 7, and hind legs were fixed and scanned with microCT. (C) BMD of the distal femur and
proximal tibia, including both cortical and trabecular bone. n=5 per group. 3D reconstructions of knee joints (D) and paws (E) from both front and
side views are displayed. * p,0.05;* *p,0.01 versus controls.
doi:10.1371/journal.pone.0015383.g007
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cultures are not (C. Yang and D.V.Novack, unpublished).
Combined, our studies of the effects of NIK loss and gain of
function indicate that NIK is a key regulator of osteolysis in the
context of inflammatory arthritis and represents an attractive
therapeutic target.
In addition to its stimulation by pathological conditions such as
arthritis, NIK can also be activated pharmacologically. Deletion of
the TRAF3 binding domain in NIK blocks its degradation by
preventing cIAP-mediated ubiquitination. Therefore, another way
to stabilize NIK protein is to block cIAPs directly with small
molecule cIAP antagonists [30,31]. In addition to their role as
inhibitors of the alternative NF-kB pathway, cIAPs also have
important pro-survival functions downstream of TNF, and
inhibition of cIAPs in many tumor cell types leads to apoptosis
[32]. Thus, cIAP antagonists are being investigated as anti-tumor
therapeutics. Our finding that NIK stabilization causes low bone
mass in growing mice and enhances inflammatory osteolysis raises
caution that cIAP antagonist drugs may have significant side
effects in bone due to OC activation.
Materials and Methods
Reagents and transgenic mice
Macrophage-colony stimulating factor (M-CSF), in the form of
CMG 14-12 supernatant, and glutathione-S-transferase RANKL
(GST-RANKL) were made as described previously [33,34].
NIKDT3 transgenic mice bearing cDNA for NIK lacking the
TRAF3 binding domain (NIKDT3) inserted into the ROSA26
locus [15] and homozygous for the transgene were mated to
heterozygous lysozyme M Cre [16] or cathepsin K Cre [19] in a
specific pathogen-free facility. All experimental protocols were
approved by the Institutional Animal Studies Committee at
Washington University School of Medicine, permit number
20080131.
Osteoclast culture
Bone marrow macrophages (BMMs) were isolated and cultured
as described [8]. BMMs were plated in the indicated doses of
GST-RANKL in the presence of 1:25 dilution of CMG 14-12
supernatant as a source of M-CSF, with media changes every 2
days, at the following cell densitities: 7.5610
3 for 96-well plates,
2610
4 for 48-well plates, for plating on bone slices, or 1.2610
6 for
10 cm
2 dishes. OC cultures were fixed in 3.7% formaldehyde and
0.1% Triton X-100 for 5 minutes, and stained for tartrate resistant
acid-phosphatase (TRAP) according to the manufacturer’s in-
structions (Sigma-Aldrich). Total cell lysates were prepared and
subjected to immunoblot analysis as described [6]. Antibodies to
NIK and p100/p52 were from Cell Signaling Technologies.
Genomic DNA preparation and PCR
DNA was extracted from cells using the XNAT REDExtract-N-
Amp Tissue PCR kit (Sigma-Aldrich), and PCR was performed
using the included PCR ReadyMix. Primers used to amplify across
the loxP-Neo
R-STOP-loxP cassette were 59-TAGGGCGCAG-
TAGTCCAGGGTTTCC-39 and 59-CATCACGGCCTTGTC-
GTCATCG-39.
Real time RT-PCR
Using the NucleoSpin RNA II kit (Machery-Nagel), total RNA
was extracted from cells. cDNA was generated from 1 mg total
RNA using Sprint RT Complete PCR tubes (Clontech) according
to the manufacturer’s instructions. RT-PCR was performed on an
ABI7300 Real-Time PCR system (Applied Biosystems) using
SYBR Advantage premix (Clontech) and the following sets of
primers: NFATc1a,5 9-GGTAACTCTGTCTTTCTAACCTTA-
AGCTC-39 and 59-GTGATGACCCCAGCATGCACCAGTC-
ACAG-39; b3-integrin,5 9-TGGTGCTCAGATGAGACTTTGTC-
39 and 59-GACTCTGGAGCACAATTGTCCTT-39; DC Stamp,
59-ACAAACAGTTCCAAAGCTTGC-39 and 59-TCCTTGGGT-
TCCTTGCTTC-39; Calcitonin Receptor,5 9-CAAGAACCTTAG-
CTGCCAGA-39 and 59-AAGACGCGGACAATGTTG-39; Gapdh,
59-CTTCACCACCATGGAGAAGGC-39 and 59-GACGGACA-
CATTGGGGGTAG-39. The amplification reaction wasperformed
for 40 cycles with denaturation at 95uC for 5 seconds, and
annealing/extension at 60uC for 31 seconds. Melt curve analysis
was performed aftereachrun. The relative abundance ofeachtarget
was calculated as 100062
2(Ct target gene2Ct Gapdh), where Ct
represents the threshold cycle for each transcript, and Gapdh is the
reference.
Bone resorption pit and actin ring staining
To visualize resorption pits, pre-osteoclasts were plated on
bovine cortical bone slices and allowed to differentiate in the
presence of RANKL and M-CSF. On the desired day, osteoclasts
were removed from the bone slices using a cotton swab/soft brush
and rinsed with PBS. The slices were then incubated at 37uC with
20mg/mL peroxidase-conjugated wheat germ agglutinin (Sigma-
Aldrich) for 30 minutes. The slices were rinsed again with PBS,
and then 3,39-diaminobenzidine was added and the slices were
incubated again for 30 minutes. Slices were then rinsed with PBS,
dried, and imaged for quantification of pit area.
For analysis of actin rings, bone slices were fixed with 4% ultra-
pure paraformaldehyde (Polysciences) and 0.2% Triton X-100 for
10 minutes, then washed with PBS 3 times. Slices were then
incubated with Alexa 488-phalloidin (Invitrogen) in the dark for
15 minutes and mounted on microscope slides. Composite
pictures were assembled in Photoshop CS2 (Adobe Systems
Incorporated) and were imported into BioQuant OSTEO 2010
(BioQuant Image Analysis Corporation) for quantification of pit or
actin ring area.
CTX (Carboxy-Terminal Collagen Crosslinks) and
Osteocalcin Assay
Prior to bleeding, mice were starved of food, but not water,
overnight. The amount of type I collagen released into serum was
measured using RatLaps
TM RIA for serum (Immunodiagnostic
Systems Ltd.). Serum osteocalcin was measured by sandwich
ELISA (Biomedical Technologies, Inc.). The culture media from
bone slices (representing 48 hours resorption) was collected and
CTX levels determined with CrossLaps for cell culture (Immu-
nodiagnostic Systems Ltd.) according to the manufacturer’s
instructions.
MicroCT analysis
Femurs or tibias were dissected out from sacrificed mice and
fixed with formalin overnight. These bones were scanned in
mCT40 microCT (Scanco Medical) at 55 kVp, 145 mA, and
16 mm resolution. Gauss sigma of 1.2, Gauss support of 2, lower
threshold of 237, and upper threshold of 1000 were used for all the
analysis. Regions of interest (ROIs) were selected 50 slices above
the growth plate of the distal femur to evaluate the trabecular
compartment. ROIs of 180 slices above and below the knee joint,
including both cortical and trabecular compartments of distal
femur and proximal tibia, were used to assess the extent of bone
erosion in the serum transfer arthritis model.
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To assess bone formation, calcein (Sigma-Aldrich) was intra-
peritoneally injected into mice at a dose of 10mg/kg body weight
on 2 and 9 days before sacrifice. Dissected femurs and tibias were
fixed with formalin. Bones were embedded in methymethacrylate
for sectioning, and then were stained for TRAP or left unstained
for analysis of calcein labels. Histomorphometric analysis was
performed by an observer blinded to genotype using standard
parameters and BioQuant OSTEO 2010 software (BioQuant
Image Analysis Corporation).
Serum Transfer Arthritis
Arthritis was induced by intraperitoneal injection of 250 mlK /
BxN serum at days 0 and 2 [22], with serum harvested prior to
injection on day 0 and at sacrifice on day 7. Ankle thickness in the
hind paws was measured daily by dial gauge (Mitutoyo).
Data Analysis
Values reported graphically are expressed as mean 6 SD, with
numbers of samples indicated in figure legends. A p-value was
obtained through the use of unpaired 1-tailed Student’s t-test. p
values are indicated in each figure, and values less than 0.05 were
considered significant.
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